Stratify patients and optimize trials with AI-driven classifiers

Challenge

Active pipeline agents with activity in SCLC are difficult to approve. Nearly all recent randomized SCLC trials show limited success.

Solution

• BostonGene refined and implemented a novel transcriptomic classification to stratify SCLC pts, improving response in all subsets.

• CLIA/CAP assay developed in 3 months.

• Assay deployed in phase III registration study.